SOLIRIS (eculizumab): The first treatment specifically approved for PNH

Ask Your Doctor About SOLIRIS

Ask Your Doctor about SOLIRIS (eculizumab)
Be well-informed when you speak to your doctor. View our Patient's Guide to SOLIRIS Therapy.

A guide for talking with your doctor about PNH and SOLIRIS

Here are some questions you may want to discuss with your doctor about PNH and SOLIRIS® (eculizumab)

  • What should I know about this disease?
     
  • What are my treatment options?
     
  • What are the benefits of these treatments?
     
  • What are the risks of these treatments?
     
  • What are the benefits of treatment with SOLIRIS?
     
  • What are the risks of treatment with SOLIRIS?

Printer-Friendly Version

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTION

SOLIRIS® increases the risk of meningococcal infections.

Patients should be vaccinated with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS. Revaccinate according to current medical guidelines for vaccine use.

Patients should be monitored closely for early signs of meningococcal infections and evaluated immediately if infection is suspected, and treated with antibiotics if necessary.

The effect of withdrawal of anticoagulant therapy during SOLIRIS treatment has not been established. Therefore, treatment with SOLIRIS should not alter anticoagulant management.

SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, fatigue, and cough.

Please see important safety information (including boxed warning) as well as the complete prescribing information.